ID

34587

Description

Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled; ODM derived from: https://clinicaltrials.gov/show/NCT01699932

Link

https://clinicaltrials.gov/show/NCT01699932

Keywords

Versions (1)
  1. 1/19/19 1/19/19 -
Copyright Holder

see on clinicaltrials.gov

Uploaded on

January 19, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Type 2 Diabetes Mellitus NCT01699932

English

Eligibility Type 2 Diabetes Mellitus NCT01699932

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with type 2 diabetes mellitus inadequately controlled despite a treatment with sulfonylurea (su) alone or metformin alone or a free combination of su and metformin prior to the study entry.
Description

ID.1

Data type

boolean

signed informed consent, obtained prior any study procedure
Description

ID.2

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
age < legal age of adulthood
Description

ID.3

Data type

boolean

hba1c < 7% or ≥ 11%
Description

ID.4

Data type

boolean

bmi > 35 kg/m2
Description

ID.5

Data type

boolean

treatment with a stable dose of maximally tolerated su alone or metformin alone or the free combination of su and metformin for less than 12 weeks prior to the screening visit.
Description

ID.6

Data type

boolean

patients who received any anti-diabetic drug other than su or metformin within 12 weeks prior to the screening visit.
Description

ID.7

Data type

boolean

diabetes other than type 2 diabetes (e.g. type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake…)
Description

ID.8

Data type

boolean

the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Description

ID.9

Data type

boolean

Back to the top of the page

Similar models

Eligibility Type 2 Diabetes Mellitus NCT01699932

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with type 2 diabetes mellitus inadequately controlled despite a treatment with sulfonylurea (su) alone or metformin alone or a free combination of su and metformin prior to the study entry.
boolean
ID.2
Item
signed informed consent, obtained prior any study procedure
boolean
Item Group
C0680251 (UMLS CUI)
ID.3
Item
age < legal age of adulthood
boolean
ID.4
Item
hba1c < 7% or ≥ 11%
boolean
ID.5
Item
bmi > 35 kg/m2
boolean
ID.6
Item
treatment with a stable dose of maximally tolerated su alone or metformin alone or the free combination of su and metformin for less than 12 weeks prior to the screening visit.
boolean
ID.7
Item
patients who received any anti-diabetic drug other than su or metformin within 12 weeks prior to the screening visit.
boolean
ID.8
Item
diabetes other than type 2 diabetes (e.g. type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake…)
boolean
ID.9
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial